Browse by topic
Subscribe to our blog

“Adherence Intelligence” is the new AI

on January 4, 2021 | By AllazoHealth
How recognizing the unique characteristics of each patient optimizes resources and maximizes impact Medication non-adherence is an age-old problem that pharmaceutical companies have been grappling with for decades. According to industry ...
Read

Two recent studies show smart pill bottles have positive impact

on November 30, 2020 | By AllazoHealth
Small study demonstrates smart pill bottles can improve adherence interventions for cancer patients A smart pill bottle platform improved adherence and patient satisfaction among a small sample of multiple myeloma patients, according to a paper in ...
Read

Solving polypharmacy non-adherence

on September 28, 2020 | By AllazoHealth
Polypharmacy, the simultaneous use of multiple drugs, is becoming more common as the population ages. More than 30% of older adults in the United States take five or more drugs, typically for multiple chronic conditions.
Read

How a.i. is optimizing medication synchronization

on September 8, 2020 | By AllazoHealth
When patients have multiple prescriptions, especially for long-term conditions, refill dates often are not aligned and create barriers to adherence. So, pharmacies have been integrating medication synchronization programs into their workflow. ...
Read

How pharma is advancing medication adherence

on August 3, 2020 | By AllazoHealth
We live in exciting times for adherence, and the pharma industry is playing a critical role, according to Mark Degatano, a pharmaceutical industry analytics expert who is on the advisory board of AllazoHealth. Degatano’s expertise comes from 24 ...
Read

How new patient data rules benefit payers

on June 22, 2020 | By AllazoHealth
Starting next year payers may have new opportunities to collect real world data that was previously fragmented, incomplete and in some cases unavailable.
Read

Healthcare AI: Why defining constraints upfront is critical

on December 12, 2019 | By AllazoHealth
AllazoHealth COO William Grambley explains in this article: “You need to be explicit about AI program constraints upfront. Otherwise you can get to unintended consequences.”
Read